103
Participants
Start Date
July 31, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
December 31, 2025
TQB2102 for injection
TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Science, Beijing
NOT_YET_RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Tsinghua Changgeng Hospital, Beijing, Beijing
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Shanghai Seventh People's Hospital, Shanghai
RECRUITING
The Third Affiliated Hospital of PLA Navy Medical University, Shanghai
NOT_YET_RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
NOT_YET_RECRUITING
Dongtai People'S Hospital, Yancheng
NOT_YET_RECRUITING
Anhui Second People's Hospital, Hefei
NOT_YET_RECRUITING
Anhui Provincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
Fuyang Cancer Hospital, Fuyang
NOT_YET_RECRUITING
Tianjin Cancer Hospital, Tianjin
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Wuhan University Zhongnan Hospital, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Jiangmen Central Hospital, Jiangmen
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
NOT_YET_RECRUITING
Tangshan People's Hospital, Tangshan
NOT_YET_RECRUITING
Chifeng City Hospital, Chifeng
NOT_YET_RECRUITING
First Hospital of Shangxi Medical University, Taiyuan
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY